Clinical Trials Logo

Clinical Trial Summary

The objective of this study was to determine the efficacy of INC424 as assessed by reduction in spleen volume in patients with primary myelofibrosis (MF), post-polycythemia vera (PV) MF, or post-essential thrombocythemia (ET) MF. The safety and tolerability of INC424 and the effects of INC424 on patient reported outcomes and the duration of response as assessed by reduction in spleen volume was also assessed.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT01392443
Study type Interventional
Source Novartis
Contact
Status Completed
Phase Phase 2
Start date October 14, 2010
Completion date October 31, 2017

See also
  Status Clinical Trial Phase
Completed NCT02087059 - A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis Phase 3